
Omeros Corporation OMER
$ 9.68
-4.63%
Quarterly report 2025-Q3
added 11-13-2025
Omeros Corporation DSO Ratio 2011-2025 | OMER
Annual DSO Ratio Omeros Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 115 | 279 | 96.5 | 106 | 176 | 265 | 86.5 | 117 | 70.7 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 279 | 70.7 | 146 |
Quarterly DSO Ratio Omeros Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 98.9 | 88.6 | 61.4 | 32.4 | 13.2 | 25.4 | 75.3 | 95.8 | 107 | 120 | 121 | 93.9 | 449 | 1.25 K | 1.14 K | 113 | 72 | 90.9 | 108 | 84.8 | 97.3 | 110 | 112 | 87 | 182 | 187 | 766 | 99.4 | 167 | 795 | 352 | 205 | 176 | 247 | 96.4 | 111 | 125 | 116 | 85.7 | 69.9 | 81 | 69.2 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.25 K | 13.2 | 204 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.85 | 2.87 % | $ 805 M | ||
|
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.21 | -1.23 % | $ 248 M | ||
|
Aptevo Therapeutics
APVO
|
79 | $ 1.06 | -6.64 % | $ 293 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
132 | $ 215.41 | -2.27 % | $ 5 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.15 | -3.85 % | $ 7.58 B | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 26.2 | 3.68 % | $ 1.27 B | ||
|
Anika Therapeutics
ANIK
|
77.3 | $ 9.59 | 0.31 % | $ 141 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 0.27 | -6.08 % | $ 588 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | ||
|
Catalyst Biosciences
CBIO
|
3.24 | $ 13.48 | -4.36 % | $ 887 M | ||
|
Axon Enterprise
AXON
|
134 | $ 549.1 | -2.69 % | $ 41.6 B | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
150 | $ 2.4 | 4.34 % | $ 15.1 M | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 11.23 | -2.69 % | $ 726 M | ||
|
Biogen
BIIB
|
57.9 | $ 174.94 | 0.48 % | $ 25.5 B | ||
|
Abeona Therapeutics
ABEO
|
387 | $ 5.07 | -5.5 % | $ 108 M | ||
|
Celldex Therapeutics
CLDX
|
86.5 | $ 27.11 | -1.47 % | $ 1.75 M | ||
|
ADiTx Therapeutics
ADTX
|
621 | $ 1.66 | -25.84 % | $ 21.9 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Фармсинтез
LIFE
|
209 | - | - | - |